This World AMR Awareness Week, we’re proud to be celebrating our collaboration with iiCON, the Infection Innovation Consortium. As a co-founder of the consortium, Infex Therapeutics and iiCON are working together to bring forward new drugs to combat antimicrobial resistance (AMR).
Against a challenging market landscape, Infex, based at Alderley Park, is forging ahead and developing vital new drugs to combat challenging global drug-resistant infections.
Working together, iiCON has supported Infex to bring 3 important new drugs to later stages of development, including Phase 2a and Phase 1 clinical trials, and these continue to progress further – offering hope to patients and communities.
Read more about our work together below: